ARZC-001

ARZC-001 is an investigational **oral, gut-restricted small molecule inhibitor** being developed by Artizan Biosciences for **inflammatory bowel disease**. The program was described as the company's lead product candidate and was discovered internally. Mechanistically, ARZC-001 is designed to **neutralize a specific secreted factor involved in microbial-driven intestinal dysregulation and inflammation**, with the goal of interrupting pathobiont-associated inflammatory cascades in the gut. The exact molecular target has not been publicly disclosed, but the therapeutic concept is positioned around microbiome-informed, precision treatment of intestinal inflammation, including diseases such as Crohn's disease and ulcerative colitis.